Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04060173
Other study ID # ABP-671-102
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 5, 2019
Est. completion date February 7, 2020

Study information

Verified date February 2020
Source Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date February 7, 2020
Est. primary completion date December 29, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subjects must be medically documented as healthy and acceptable at screening.

- Subjects must have serum uric acid level at screening = 7.0 mg/dL for men, = 6.0 mg/dL for women.

- Subjects must have a Body Mass Index (BMI) between 18.0 and 34.0 kg/m2 (inclusive).

- Subjects must have a body weight of 50 kg or higher.

- The subject agrees to abstain from alcohol consumption for 48 hours prior to dosing, for the duration of the in-house study period, and for 48 hours prior to each in-clinic follow up visit.

- The subject is a nonsmoker.

- Women must be non-pregnant and non-lactating, and either surgically sterile or postmenopausal for = 12 months.

- Men must be surgically sterile, abstinent or if engaged in sexual relations with a female partner of child-bearing potential, the participant must be using a condom with spermicide from Screening and for a period of 30 days after the last dose of Study Drug. The Investigator will assess the adequacy of methods of contraception on a case-by-case basis.

- Subjects must have a complete blood count (CBC) and platelet count within the normal range or considered not clinically significant by the principal investigator.

- Other than elevated serum uric acid, subjects must have normal blood chemistry or results considered not clinically significant by the investigator.

- Subjects must have a normal urinalysis or results considered not clinically significant by the investigator including a normal protein/creatinine ratio per local lab reference ranges (= 200 mg/g) and a urine creatinine result that does not exceed 300 mg/dL. Any out of range values may be repeated per Investigator discretion.

- Subjects must have a normal ECG or results considered not clinically significant by the principal investigator.

- Subjects must be able to comply with the study and follow-up procedures.

- Subjects are able to understand the study procedures and risks involved and must provide signed informed consent to participate in the study.

Exclusion Criteria:

- Subjects with any history or clinical manifestations of significant metabolic, hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders.

- Subjects who are positive for human immunodeficiency virus (HIV), Hepatitis B surface antigen, and/or Hepatitis C virus.

- Subjects who have used prescription drugs, over-the-counter drugs, or herbal remedies within 3 weeks before Day 1 of study medication dosing.

- Subjects who are positive for urine drug and alcohol screening tests.

- Subjects who have undergone major surgery within 3 months prior to Day 1.

- Women who are pregnant or breastfeeding.

- Subjects who received any investigational test article within 5 half-lives or 30 days, whichever is longer, prior to Day 1 study medication dosing.

- Recent blood donation for more than 500 mL within 2 months of screening.

- Abnormal ECG including QTc > 470 (F) and > 450 (M).

- Subjects who consumed Seville oranges- or grapefruit-containing foods or beverages within 7 days before Day 1 and during the entire study duration.

- Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.

- Prior exposure to ABP-671.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ABP-671
ABP-671 is an investigational drug
Other:
Placebo
Matching placebo

Locations

Country Name City State
United States Celerion Tempe Arizona

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events (AEs) Measured by the number of patients with AEs 38 days
Secondary Maximum observed plasma concentration of ABP-671 (Cmax) 2 weeks
Secondary Area under time-concentration curve (AUC) 2 weeks
Secondary Time of maximum observed plasma concentration of ABP-671 (Tmax) 2 weeks
Secondary Volume of distribution (Vd) 2 weeks
Secondary Half life of ABP-671 (t1/2) 2 weeks
Secondary The effect of ABP-671 versus placebo on the percent change from baseline in serum uric acid 24 days
Secondary The effect of ABP-671 versus placebo on change in urine uric acid excretion 24 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06187519 - UR+AIMS Gout Wearable Skin Uric Acid Monitor Study N/A
Completed NCT03635957 - Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Phase 4
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT03015948 - A Single Dose Study of SHR4640 in Healthy Male Volunteers Phase 1
Completed NCT02855437 - Novel Methods for Ascertainment of Gout Flares -A Pilot Study N/A
Active, not recruiting NCT02702375 - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases N/A
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT00995618 - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Phase 2
Completed NCT00985127 - Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout Phase 2
Terminated NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease Phase 2
Completed NCT03291782 - D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers Phase 1
Recruiting NCT03388515 - A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects. Phase 1
Completed NCT06189404 - Effect of Tigulixostat on the Pharmacokinetics of Theophylline Phase 1
Enrolling by invitation NCT03336203 - The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Phase 4
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Recruiting NCT04047394 - A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers Phase 1
Not yet recruiting NCT05507723 - Tight Control of Gouty Arthritis Compared to Usual Care N/A
Recruiting NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia Phase 1/Phase 2
Completed NCT02557126 - Study of URC102 to Assess the Safety and Efficacy in Gout Patients Phase 2
Completed NCT02246673 - RDEA3170 and Febuxostat Combination Study in Gout Subjects Phase 2